101
|
Fukuda M, Nakamura Y, Kasai T, Kinoshita A, Fukuda M, Motoshima K, IIda T, Nakatomi K, Soda H, Oka M, Kohno S. A phase I study of amrubicin and carboplatin for previously untreated patients with extensive stage small-cell lung cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.19070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
102
|
Morita K, Maeda N, Kawaoka T, Hiraki S, Kudo A, Fukuda S, Oka M. Effects of the time interval between clamping and linear stapling for resection of porcine small intestine. Surg Endosc 2008; 22:750-6. [PMID: 17694412 DOI: 10.1007/s00464-007-9481-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
BACKGROUND Although a wait of several seconds after clamping is recommended when an automatic stapler is used to achieve adequate hemostasis, this wait has not been experimentally clarified. METHODS To determine whether waiting is necessary between clamping and firing of a linear stapler, this study evaluated the number of staple line bleeding points and histologic changes in stapling sites of porcine small intestine (n = 46). It also assessed the ratio of dry to wet tissue weight (DW ratio) (n = 20) of porcine small intestine clamped between the prongs of a linear stapler. The sites were studied separately as follows: no wait with a four-row device (n = 12), no wait with a six-row device (n = 11), wait with a four-row device (n = 12), and wait with a six-row device (n = 11). The linear stapler was fired immediately after clamping in the no wait group and 1 min after clamping in the wait group. RESULTS The mean number of staple line bleeding points in 2 to 5 min with the six-row device and in 3 to 5 min with the four-row device after firing were significantly less in the wait group than in the no wait group using the same device (p < 0.05). Cross sections of staple lines showed a higher frequency of mucosal cutting in the no wait group than in the wait group for both the four-row and the six-row devices (both significant at p < 0.01). Although the mean wet tissue weights of anastomotic sites did not change in either group, the mean DW ratio was significantly less in the wait group than in the no wait group (p < 0.01). CONCLUSIONS A 1-min interval after clamping decreases the amount of clamped tissue. Waiting may thus be necessary to reduce bleeding from stapling sites, which may be related to a decrease in mucosal cutting.
Collapse
|
103
|
Ikee R, Oka M, Maesato K, Mano T, Moriya H, Ohtake T, Kobayashi S. Eosinophilic peritonitis and ultrafiltration failure on initiation of CAPD. Perit Dial Int 2008; 28:197-199. [PMID: 18332458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023] Open
|
104
|
Sakai S, Matsuda R, Adachi R, Akiyama H, Maitani T, Ohno Y, Oka M, Abe A, Seiki K, Oda H, Shiomi K, Urisu A. Interlaboratory evaluation of two enzyme-linked immunosorbent assay kits for the determination of crustacean protein in processed foods. J AOAC Int 2008; 91:123-129. [PMID: 18376594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
The labeling of foods containing material derived from crustaceans such as shrimp and crab is to become mandatory in Japan because of increases in the number of allergy patients. To ensure proper labeling, 2 novel sandwich enzyme-linked immunosorbent assay (ELISA) kits for the determination of crustacean protein in processed foods, the N kit (Nissui Pharmaceutical Co., Ltd, Ibaraki, Japan) and the M kit (Maruha Nichiro Holdings, Inc., Ibaraki, Japan), have been developed. Five types of model processed foods containing 10 and/or 11.9 microg/g crustacean soluble protein were prepared for interlaboratory evaluation of the performance of these kits. The N kit displayed a relatively high level of reproducibility relative standard deviation (interlaboratory precision; 4.0-8.4% RSDR) and sufficient recovery (65-86%) for all the model processed foods. The M kit displayed sufficient reproducibility (17.6-20.5% RSDR) and a reasonably high level of recovery (82-103%). The repeatability relative standard deviation (RSDr) values regarding the detection of crustacean proteins in the 5 model foods were mostly < 5.1% RSDr for the N kit and 9.9% RSDr for the M kit. In conclusion, the results of this interlaboratory evaluation suggest that both these ELISA kits would be very useful for detecting crustacean protein in processed foods.
Collapse
|
105
|
|
106
|
|
107
|
Liu TL, Shimada H, Ochiai T, Shiratori T, Lin SE, Kitagawa M, Harigaya K, Maki M, Oka M, Abe T, Takiguchi M, Hiwasa T. Enhancement of chemosensitivity toward peplomycin by calpastatin-stabilized NF-kappaB p65 in esophageal carcinoma cells: possible involvement of Fas/Fas-L synergism. Apoptosis 2007; 11:1025-37. [PMID: 16547594 DOI: 10.1007/s10495-006-6353-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Chemosensitivity to anticancer drugs was compared between two human esophageal carcinoma cell lines, T.Tn and YES-6 cells. T.Tn cells were more resistant than YES-6 cells to peplomycin (PEP) but not to the other anticancer drugs such as camptothecin, mitomycin C and cytosine arabinoside. Western blot analysis showed higher expression levels of m-calpain and activated mu-calpain in T.Tn cells than in YES-6 cells. On the other hand, YES-6 cells showed a high expression level of calpastatin, which is a calpain-specific endogenous inhibitor. To investigate whether calpain activity was involved in the chemosensitivity, T.Tn cells were transfected with calpastatin cDNA in an inducible expression vector. The induction of calpastatin was accompanied by increased chemosensitivity to PEP. The increases in calpastatin levels were followed by serial increases in the expression levels of NF-kappaB p65 and Fas. Since purified m- or mu-calpain degraded NF-kappaB p65 in vitro, it is possible that calpastatin suppressed calpain-mediated degradation of NF-kappaB p65. Fas ligand (Fas-L) protein levels increased after treatment of the parental T.Tn and calpastatin-transfected cells with PEP, suggesting the synergism between calpastatin-induced Fas and PEP-induced Fas-L. These results suggest that calpain/calpastatin expression levels are effective markers for predicting the sensitivity of human esophageal carcinoma cells to PEP.
Collapse
|
108
|
Kobashi Y, Mouri K, Obase Y, Fukuda M, Miyashita N, Oka M. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients. Eur Respir J 2007; 30:945-50. [PMID: 17652312 DOI: 10.1183/09031936.00040007] [Citation(s) in RCA: 79] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The usefulness of the tuberculin skin test (TST) and the QuantiFERON TB-2G (QFT-TB) test were compared in immunocompromised patients. The subjects consisted of 252 immunocompromised patients who were clinically suspected of tuberculosis (TB) infection between April 2005 and December 2006. Regarding the underlying diseases, 74 subjects had malignant diseases, 72 were undergoing immunosuppressive treatment, 52 had diabetes mellitus, 50 had chronic renal failure and four had HIV infection. While the positive rate of the QFT-TB test for the diagnosis of TB infection (TB disease or latent TB infection) was 78.1%, that of TST for TB infection was 50.0%. The QFT-TB test was significantly better than TST. However, 32 (13%) patients had an indeterminate QFT-TB result. Indeterminate findings were significantly more frequent in patients receiving immunosuppressive treatment (28%), especially with lymphocytopaenia in the peripheral blood, than in those who had other underlying diseases. While TST-positive and QFT-TB test-negative results were recognised in immunocompromised patients with bacille Calmette-Guérin vaccination or nontuberculous mycobacterial disease, TST-negative and QFT-TB test-positive results were recognised in immunocompromised patients with a past history of TB infection. It was concluded that the QuantiFERON TB-2G test is a more useful diagnostic method for tuberculosis infection than tuberculin skin test for immunocompromised patients suspected of tuberculosis disease. However, because the results of the QuantiFERON TB-2G test show an indeterminate response for patients receiving immunosuppressive treatment, especially for those with lymphocytopaenia due to severe underlying diseases, care must be taken in the interpretation of the QuantiFERON TB-2G test for these patients.
Collapse
|
109
|
Kobayashi K, Oka M, Akiyama T, Inoue T, Abiru K, Ogino T, Yoshinaga H, Ohtsuka Y, Oka E. Rhythmic 60–100Hz activity on scalp EEG associated with epileptic spasms. Clin Neurophysiol 2007. [DOI: 10.1016/j.clinph.2007.06.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
110
|
Kobayashi K, Inoue T, Kikumoto K, Endoh F, Miya K, Oka M, Yoshinaga H, Ohtsuka Y. Relation of spasms and myoclonus to suppression-burst on EEG in epileptic encephalopathy in early infancy. Neuropediatrics 2007; 38:244-50. [PMID: 18330839 DOI: 10.1055/s-2008-1062716] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
PURPOSE This study was intended to clarify the relation between spasms in series and a suppression-burst (SB) EEG pattern which have a common nature of repetitive bursting activity in epileptic encephalopathy in early infancy. METHODS The ictal EEG traces of spasms were temporally compressed and expanded to study the beginning and ending phases of series along with their spectral analysis in two patients with Ohtahara syndrome (OS) and one with early myoclonic encephalopathy (EME). The EEG bursts associated with myoclonus were also investigated. RESULTS A mutual transition was indicated between the ictal activity of spasms and the bursts in the peri-series SB on EEG. Gamma rhythm was detected in common in the ictal activity and the peri-series and interictal bursts on EEG, and also in the bursts with myoclonus. CONCLUSION The relation between the ictal activity of spasms and SB on EEG was shown to be close. The generative mechanisms of spasms and myoclonus might be linked to the bursting tendency intrinsic to immature brain function.
Collapse
|
111
|
Asaoka Y, Yoshida K, Oka M, Shinomura T, Mishima H, Matsushima S, Nishizuka Y. The signal-induced phospholipid degradation cascade and protein kinase C activation. CIBA FOUNDATION SYMPOSIUM 2007; 164:50-9; discussion 59-65. [PMID: 1395935 DOI: 10.1002/9780470514207.ch5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Acting in synergy with diacylglycerol, unsaturated free fatty acids such as arachidonic, oleic, linoleic, linolenic and docosahexaenoic acids dramatically activate some members of the protein kinase C family at the basal level of Ca2+ concentration. It is plausible that phospholipase C and phospholipase A2, and possibly phospholipase D as well, are involved in the activation of protein kinase C. Presumably, this enzyme activation is integrated into the signal-induced membrane phospholipid degradation cascade, prolonging the activation of protein kinase C. The sustained activity of this enzyme appears to be of importance for long-term cellular responses such as development of neuronal plasticity and gene activation.
Collapse
|
112
|
Yoshino S, Nishimura T, Hazama S, Oka M, Ozasa H, Shimizu R, Furuya T, Fukuda S, Satoh T, Hara T. A combination chemotherapy of weekly paclitaxel and doxifluridine (5’-DFUR: an intermediate metabolite of capecitabine) in patients with unresectable or recurrent gastric cancer in an outpatient setting. Final results of a multicenter phase II trial. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15050 Background: Paclitaxel (PTX) and 5’-DFUR have single-agent activity in gastric cancer and have distinct mechanisms of action and no overlap of key toxicities. Synergistic interaction between PTX and 5’-DFUR is mediated by taxane-induced up-regulation of thymidine phosphorylase, which converts 5’-DFUR to 5-FU. We conducted a combination phase II study of PTX and 5’-DFUR in patients with unresectable or recurrent gastric cancer to evaluate the efficacy and safety in an outpatient. Methods: Eligibility criteria included patients with histologically proven unresectable or recurrent gastric cancer who had measurable lesions fitting RECIST, up to one prior chemotherapy, a performance status of 0–2 and adequate organ function. According to our results of phase I study (Proc ASCO 2004, Abstr. 4228), the treatment included PTX 70 mg/m2 i.v. on days 1, 8, and 15 every 4 weeks and 5’-DFUR 600 mg/body p.o. everyday until there was disease progression or the appearance of unacceptable toxicity. Primary endpoint was: RR; and secondary endpoints were OS, PFS, TTF and onset rate of adverse events. Results: Between June 2004 and July 2006, 42 patients were enrolled in this study: including 34 men; 8 women; median age of 70 years (range, 44–85 years); and PS levels were, zero with 27, one with 13 and two with 2 patients. In 42 eligible patients, clinical usefulness was evaluated resulting in response rate of 40.5% (CR, 1; PR, 16; SD, 17; PD, 6; and NE, 2 patients). The first-line therapy involved 28 patients in whom the response rate was 50.0%. The second-line therapy involved 13 patients (all TS-1 failure) in whom the response rate was 23.1%. OS was 371 days, PFS was 170 days and TTF was 147 days. All patients were treated in outpatient. Severe adverse events were found in 2 patients to discontinue the present treatment, though other adverse events were relatively mild without death due to the present therapy. Commonly observed grade 3/4 adverse events were neutropenia (26.2%), appetite loss (4.8%), neuropathy (4.8%), and fatigue (4.8%). Conclusions: The outpatient combination of a weekly PTX and 5’-DFUR chemotherapy is active and well tolerated. No significant financial relationships to disclose.
Collapse
|
113
|
Fukuda M, Soda H, Nakamura Y, Fukuda M, Kinoshita A, Nagashima S, Nakano H, Yamaguchi H, Kohno S, Oka M. Phase II trial of irinotecan plus cisplatin with concurrent thoracic radiotherapy (TRT) in patients with previously untreated locally advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18071 Background: The combined modality of the third generation new agent plus cisplatin with concurrent TRT is considered ideal for locally advanced non-small cell lung cancer. However, it is difficult to conduct because of severe toxicities. Methods: Patients fulfilling the following eligibility criteria were enrolled: previously untreated, good performance status (PS 0–2), age <75, stage III, and adequate organ function. The patients received irinotecan 60 mg/m2 i.v. on days 1, 8 and 15, and cisplatin 80 mg/m2 i.v. on day 1 in the first group. The doses were reduced to 50 and 60 mg/m2 in the second group, respectively. Two cycles of chemotherapy were repeated every 4 weeks. Thoracic radiotherapy of 2 Gy/day commenced on day 2 of each chemotherapy cycle, with 28 and 32 Gy administered in the first and second cycles, respectively. Primary endpoint and objective sample size were response rate and 45 patients, respectively. Results: Fifty patients were eligible and 48 (16 in the 1st, 32 in the 2nd group) patients were assessable for response, toxicity and survival. The overall response (OS) was 83% (95% confidence interval (CI), 70–93%). Grade 4 leukopenia, neutropenia, grade 3 or 4 diarrhea, pneumonitis, esophagitis and fatigue occurred in 21%, 48%, 19%, 10% and 19%, respectively. The median time to progression was 8.2 months. The median overall survival time (MST), and the 2- and 5-year survival rates were 20.1 months, 47.1% and 17.1%, respectively. In subgroup analysis, the OS of 1st and 2nd groups were 75% and 88% (not significant), respectively. The MST of 1st and 2nd groups were 13.1 and 33.4 months, respectively, and significant favor with 2nd group (p=0.011). The execution rates of irinotecan on day 15 were significant higher in 2nd (22% vs. 48%) groups (p=0.032), and the survival separated by execution times on day 15 were significantly favor with higher execution time group (p=0.026). Conclusions: This therapy is active and further investigations are warranted at the 2nd group dose level. High execution of chemotherapy on day 15 may be important for the achievement of concurrent chemoradiotherapy. No significant financial relationships to disclose.
Collapse
|
114
|
Hazama S, Koudo H, Yoshida S, Shimizu R, Ozasa H, Yamamoto T, Araki A, Yoshino S, Okayama N, Hinoda Y, Oka M. UGT1As polymorphisms predict toxicity in colorectal cancer patients treated with different recommended doses of irinotecan oriented by UGT1A1*28 polymorphism based on previous phase I study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.14511] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14511 Background: We have presented at 2006 ASCO annual meeting about a genetic UGT1A1 polymorphism oriented phase (P) I study of Irinotecan and 5’-DFUR for metastatic colorectal cancer (MCRC) to determine the maximum tolerated dose (MTD) and the recommend doses (RD) for each UGT1A1 *1/*1 and *1/*28 genotypes. The RD of biweekly Irinotecan administration was 150 mg/m2 for patients (pts) with wild *1/*1 genotype and 70 mg/m2 of Irinotecan for mutated *1/*28. Now we are carrying out a *28 oriented P II study based on this RD. Here we report the profiles of toxicities in the P II study of irinotecan and 5’-DFUR to analyze other kinds of UGT1As polymorphisms in relation to irinotecan toxicities. Patients & Methods: Eligibility criteria were as follows; histologically proven CRC with unresectable metastatic lesions, PS 0–1, age<76, adequate organ functions, and written informed consent. Twenty one pts with wild type genotype and 9 pts with mutated genotype were enrolled. Irinotecan was infused 150 mg/m2 for pts with *1/*1 genotype and 70 mg/m2 for *1/*28. Hematological and non-hematological toxicities were graded, and UGT1As polymorphisms (UGT1A1*6 and *7, UGT1A7*1*2*3*4, UGT1A9*22) were analyzed. Results: Grade (G)3 & 4 toxicities were observed in 6 of 22 (27%) wild type pts and in 3 of 9 (33%) mutated pts, and in 9 of 31 (29%) all pts. There was no significant difference on the profiles of toxicities between the pts with wild genotype and mutated genotype, irrespective of the difference of the quantity of irinotecan. So, the RD was thought to be adequate. In pts with UGT1A1*6 allele, G3 & 4 toxicities were observed 6/11 (55%), on the other hand 3/20 (15%) in pts without *6 allele (p=0.038). G3 & 4 toxicities were also more frequent in pts with UGT1A7*3 alleles than pts without *3 allele (p<0.10). Conclusions: The profiles of toxicities of pts with *1/*1 or *1/*28 genotypes were similar irrespective of the difference of the quantity of irinotecan. The result indicated that the RD of latest PI for each group was adequate, and this P II study is suitable to analyze other kinds of polymorphisms that have correlation to irinotecan toxicities. UGT1A1*6 and UGT1A7*3 allele will be a novel predictor for toxicity of irinotecan. No significant financial relationships to disclose.
Collapse
|
115
|
Adare A, Adler SS, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Al-Jamel A, Aoki K, Aphecetche L, Armendariz R, Aronson SH, Asai J, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Baksay G, Baksay L, Baldisseri A, Barish KN, Barnes PD, Bassalleck B, Bathe S, Batsouli S, Baublis V, Bauer F, Bazilevsky A, Belikov S, Bennett R, Berdnikov Y, Bickley AA, Bjorndal MT, Boissevain JG, Borel H, Boyle K, Brooks ML, Brown DS, Bruner N, Bucher D, Buesching H, Bumazhnov V, Bunce G, Burward-Hoy JM, Butsyk S, Camard X, Campbell S, Chai JS, Chand P, Chang BS, Chang WC, Charvet JL, Chernichenko S, Chiba J, Chi CY, Chiu M, Choi IJ, Choudhury RK, Chujo T, Chung P, Churyn A, Cianciolo V, Cleven CR, Cobigo Y, Cole BA, Comets MP, Constantin P, Csanád M, Csörgo T, Cussonneau JP, Dahms T, Das K, David G, Deák F, Deaton MB, Dehmelt K, Delagrange H, Denisov A, d'Enterria D, Deshpande A, Desmond EJ, Devismes A, Dietzsch O, Dion A, Donadelli M, Drachenberg JL, Drapier O, Drees A, Dubey AK, Durum A, Dutta D, Dzhordzhadze V, Efremenko YV, Egdemir J, Ellinghaus F, Emam WS, Enokizono A, En'yo H, Espagnon B, Esumi S, Eyser KO, Fields DE, Finck C, Finger M, Finger M, Fleuret F, Fokin SL, Forestier B, Fox BD, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fung SY, Fusayasu T, Gadrat S, Garishvili I, Gastineau F, Germain M, Glenn A, Gong H, Gonin M, Gosset J, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Gustafsson HA, Hachiya T, Hadj Henni A, Haegemann C, Haggerty JS, Hagiwara MN, Hamagaki H, Han R, Hansen AG, Harada H, Hartouni EP, Haruna K, Harvey M, Haslum E, Hasuko K, Hayano R, Heffner M, Hemmick TK, Hester T, Heuser JM, He X, Hidas P, Hiejima H, Hill JC, Hobbs R, Hohlmann M, Holmes M, Holzmann W, Homma K, Hong B, Hoover A, Horaguchi T, Hornback D, Hur MG, Ichihara T, Ikonnikov VV, Imai K, Inaba M, Inoue Y, Inuzuka M, Isenhower D, Isenhower L, Ishihara M, Isobe T, Issah M, Isupov A, Jacak BV, Jia J, Jin J, Jinnouchi O, Johnson BM, Johnson SC, Joo KS, Jouan D, Kajihara F, Kametani S, Kamihara N, Kamin J, Kaneta M, Kang JH, Kanou H, Katou K, Kawabata T, Kawagishi T, Kawall D, Kazantsev AV, Kelly S, Khachaturov B, Khanzadeev A, Kikuchi J, Kim DH, Kim DJ, Kim E, Kim GB, Kim HJ, Kim YS, Kinney E, Kiss A, Kistenev E, Kiyomichi A, Klay J, Klein-Boesing C, Kobayashi H, Kochenda L, Kochetkov V, Kohara R, Komkov B, Konno M, Kotchetkov D, Kozlov A, Král A, Kravitz A, Kroon PJ, Kubart J, Kuberg CH, Kunde GJ, Kurihara N, Kurita K, Kweon MJ, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Lebedev A, Le Bornec Y, Leckey S, Lee DM, Lee MK, Lee T, Leitch MJ, Leite MAL, Lenzi B, Lim H, Liska T, Litvinenko A, Liu MX, Li X, Li XH, Love B, Lynch D, Maguire CF, Makdisi YI, Malakhov A, Malik MD, Manko VI, Mao Y, Martinez G, Masek L, Masui H, Matathias F, Matsumoto T, McCain MC, McCumber M, McGaughey PL, Miake Y, Mikes P, Miki K, Miller TE, Milov A, Mioduszewski S, Mishra GC, Mishra M, Mitchell JT, Mitrovski M, Mohanty AK, Morreale A, Morrison DP, Moss JM, Moukhanova TV, Mukhopadhyay D, Muniruzzaman M, Murata J, Nagamiya S, Nagata Y, Nagle JL, Naglis M, Nakagawa I, Nakamiya Y, Nakamura T, Nakano K, Newby J, Nguyen M, Norman BE, Nyanin AS, Nystrand J, O'Brien E, Oda SX, Ogilvie CA, Ohnishi H, Ojha ID, Okada H, Okada K, Oka M, Omiwade OO, Oskarsson A, Otterlund I, Ouchida M, Oyama K, Ozawa K, Pak R, Pal D, Palounek APT, Pantuev V, Papavassiliou V, Park J, Park WJ, Pate SF, Pei H, Penev V, Peng JC, Pereira H, Peresedov V, Peressounko DY, Pierson A, Pinkenburg C, Pisani RP, Purschke ML, Purwar AK, Qualls JM, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Rembeczki S, Reuter M, Reygers K, Riabov V, Riabov Y, Roche G, Romana A, Rosati M, Rosendahl SSE, Rosnet P, Rukoyatkin P, Rykov VL, Ryu SS, Sahlmueller B, Saito N, Sakaguchi T, Sakai S, Sakata H, Samsonov V, Sanfratello L, Santo R, Sato HD, Sato S, Sawada S, Schutz Y, Seele J, Seidl R, Semenov V, Seto R, Sharma D, Shea TK, Shein I, Shevel A, Shibata TA, Shigaki K, Shimomura M, Shohjoh T, Shoji K, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh CP, Singh V, Skutnik S, Slunecka M, Smith WC, Soldatov A, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Staley F, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Suire C, Sullivan JP, Sziklai J, Tabaru T, Takagi S, Takagui EM, Taketani A, Tanaka KH, Tanaka Y, Tanida K, Tannenbaum MJ, Taranenko A, Tarján P, Thomas TL, Togawa M, Toia A, Tojo J, Tomásek L, Torii H, Towell RS, Tram VN, Tserruya I, Tsuchimoto Y, Tuli SK, Tydesjö H, Tyurin N, Uam TJ, Vale C, Valle H, vanHecke HW, Velkovska J, Velkovsky M, Vertesi R, Veszprémi V, Vinogradov AA, Virius M, Volkov MA, Vrba V, Vznuzdaev E, Wagner M, Walker D, Wang XR, Watanabe Y, Wessels J, White SN, Willis N, Winter D, Wohn FK, Woody CL, Wysocki M, Xie W, Yamaguchi YL, Yanovich A, Yasin Z, Ying J, Yokkaichi S, Young GR, Younus I, Yushmanov IE, Zajc WA, Zaudtke O, Zhang C, Zhou S, Zimányi J, Zolin L, Zong X. System size and energy dependence of jet-induced hadron pair correlation shapes in Cu+Cu and Au+Au collisions at square root sNN=200 and 62.4 GeV. PHYSICAL REVIEW LETTERS 2007; 98:232302. [PMID: 17677902 DOI: 10.1103/physrevlett.98.232302] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/12/2006] [Indexed: 05/16/2023]
Abstract
We present azimuthal angle correlations of intermediate transverse momentum (1-4 GeV/c) hadrons from dijets in Cu+Cu and Au+Au collisions at square root sNN=62.4 and 200 GeV. The away-side dijet induced azimuthal correlation is broadened, non-Gaussian, and peaked away from Delta phi=pi in central and semicentral collisions in all the systems. The broadening and peak location are found to depend upon the number of participants in the collision, but not on the collision energy or beam nuclei. These results are consistent with sound or shock wave models, but pose challenges to Cherenkov gluon radiation models.
Collapse
|
116
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Aoki K, Aphecetche L, Armendariz R, Aronson SH, Asai J, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Baksay G, Baksay L, Baldisseri A, Barish KN, Barnes PD, Bassalleck B, Bathe S, Batsouli S, Baublis V, Bazilevsky A, Belikov S, Bennett R, Berdnikov Y, Bickley AA, Boissevain JG, Borel H, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Campbell S, Chang BS, Charvet JL, Chernichenko S, Chiba J, Chi CY, Chiu M, Choi IJ, Chujo T, Chung P, Churyn A, Cianciolo V, Cleven CR, Cole BA, Comets MP, Constantin P, Csanád M, Csörgo T, Dahms T, Das K, David G, Deaton MB, Dehmelt K, Delagrange H, Denisov A, d'Enterria D, Deshpande A, Desmond EJ, Dietzsch O, Dion A, Donadelli M, Drapier O, Drees A, Dubey AK, Durum A, Dzhordzhadze V, Efremenko YV, Egdemir J, Ellinghaus F, Emam WS, Enokizono A, En'yo H, Esumi S, Eyser KO, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fusayasu T, Gadrat S, Garishvili I, Glenn A, Gong H, Gonin M, Gosset J, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Gustafsson HA, Hachiya T, Hadj Henni A, Haegemann C, Haggerty JS, Hamagaki H, Han R, Harada H, Hartouni EP, Haruna K, Haslum E, Hayano R, Heffner M, Hemmick TK, Hester T, He X, Hiejima H, Hill JC, Hobbs R, Hohlmann M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Ichihara T, Imai K, Inaba M, Inoue Y, Isenhower D, Isenhower L, Ishihara M, Isobe T, Issah M, Isupov A, Jacak BV, Jia J, Jin J, Jinnouchi O, Johnson BM, Joo KS, Jouan D, Kajihara F, Kametani S, Kamihara N, Kamin J, Kaneta M, Kang JH, Kanou H, Kawall D, Kazantsev AV, Khanzadeev A, Kikuchi J, Kim DH, Kim DJ, Kim E, Kinney E, Kiss A, Kistenev E, Kiyomichi A, Klay J, Klein-Boesing C, Kochenda L, Kochetkov V, Komkov B, Konno M, Kotchetkov D, Kozlov A, Král A, Kravitz A, Kubart J, Kunde GJ, Kurihara N, Kurita K, Kweon MJ, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Lebedev A, Lee DM, Lee MK, Lee T, Leitch MJ, Leite MAL, Lenzi B, Liska T, Litvinenko A, Liu MX, Li X, Love B, Lynch D, Maguire CF, Makdisi YI, Malakhov A, Malik MD, Manko VI, Mao Y, Masek L, Masui H, Matathias F, McCumber M, McGaughey PL, Miake Y, Mikes P, Miki K, Miller TE, Milov A, Mioduszewski S, Mishra M, Mitchell JT, Mitrovski M, Morreale A, Morrison DP, Moukhanova TV, Mukhopadhyay D, Murata J, Nagamiya S, Nagata Y, Nagle JL, Naglis M, Nakagawa I, Nakamiya Y, Nakamura T, Nakano K, Newby J, Nguyen M, Norman BE, Nyanin AS, O'Brien E, Oda SX, Ogilvie CA, Ohnishi H, Okada H, Okada K, Oka M, Omiwade OO, Oskarsson A, Ouchida M, Ozawa K, Pak R, Pal D, Palounek APT, Pantuev V, Papavassiliou V, Park J, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Pinkenburg C, Purschke ML, Purwar AK, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Rembeczki S, Reuter M, Reygers K, Riabov V, Riabov Y, Roche G, Romana A, Rosati M, Rosendahl SSE, Rosnet P, Rukoyatkin P, Rykov VL, Sahlmueller B, Saito N, Sakaguchi T, Sakai S, Sakata H, Samsonov V, Sato S, Sawada S, Seele J, Seidl R, Semenov V, Seto R, Sharma D, Shein I, Shevel A, Shibata TA, Shigaki K, Shimomura M, Shoji K, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh CP, Singh V, Skutnik S, Slunecka M, Soldatov A, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Staley F, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Suire C, Sziklai J, Tabaru T, Takagi S, Takagui EM, Taketani A, Tanaka Y, Tanida K, Tannenbaum MJ, Taranenko A, Tarján P, Thomas TL, Togawa M, Toia A, Tojo J, Tomásek L, Torii H, Towell RS, Tram VN, Tserruya I, Tsuchimoto Y, Vale C, Valle H, van Hecke HW, Velkovska J, Vertesi R, Vinogradov AA, Virius M, Vrba V, Vznuzdaev E, Wagner M, Walker D, Wang XR, Watanabe Y, Wessels J, White SN, Winter D, Woody CL, Wysocki M, Xie W, Yamaguchi Y, Yanovich A, Yasin Z, Ying J, Yokkaichi S, Young GR, Younus I, Yushmanov IE, Zajc WA, Zaudtke O, Zhang C, Zhou S, Zimányi J, Zolin L. J/psi production versus transverse momentum and rapidity in p+p collisions at square root s=200 GeV. PHYSICAL REVIEW LETTERS 2007; 98:232002. [PMID: 17677900 DOI: 10.1103/physrevlett.98.232002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/12/2006] [Indexed: 05/16/2023]
Abstract
J/psi production in p+p collisions at square root s=200 GeV has been measured by the PHENIX experiment at the BNL Relativistic Heavy Ion Collider over a rapidity range of -2.2<y<2.2 and a transverse momentum range of 0<pT<9 GeV/c. The size of the present data set allows a detailed measurement of both the pT and the rapidity distributions and is sufficient to constrain production models. The total cross section times the branching ratio is Bll sigma pp J/psi=178+/-3stat+/-53sys+/-18norm nb.
Collapse
|
117
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Al-Jamel A, Aoki K, Aphecetche L, Armendariz R, Aronson SH, Asai J, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Baksay G, Baksay L, Baldisseri A, Barish KN, Barnes PD, Bassalleck B, Bathe S, Batsouli S, Baublis V, Bauer F, Bazilevsky A, Belikov S, Bennett R, Berdnikov Y, Bickley AA, Bjorndal MT, Boissevain JG, Borel H, Boyle K, Brooks ML, Brown DS, Bucher D, Buesching H, Bumazhnov V, Bunce G, Burward-Hoy JM, Butsyk S, Campbell S, Chai JS, Chang BS, Charvet JL, Chernichenko S, Chiba J, Chi CY, Chiu M, Choi IJ, Chujo T, Chung P, Churyn A, Cianciolo V, Cleven CR, Cobigo Y, Cole BA, Comets MP, Constantin P, Csanád M, Csörgo T, Dahms T, Das K, David G, Deaton MB, Dehmelt K, Delagrange H, Denisov A, d'Enterria D, Deshpande A, Desmond EJ, Dietzsch O, Dion A, Donadelli M, Drachenberg JL, Drapier O, Drees A, Dubey AK, Durum A, Dzhordzhadze V, Efremenko YV, Egdemir J, Ellinghaus F, Emam WS, Enokizono A, En'yo H, Espagnon B, Esumi S, Eyser KO, Fields DE, Finger M, Fleuret F, Fokin SL, Forestier B, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fung SY, Fusayasu T, Gadrat S, Garishvili I, Gastineau F, Germain M, Glenn A, Gong H, Gonin M, Gosset J, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Gustafsson HA, Hachiya T, Hadj Henni A, Haegemann C, Haggerty JS, Hagiwara MN, Hamagaki H, Han R, Harada H, Hartouni EP, Haruna K, Harvey M, Haslum E, Hasuko K, Hayano R, Heffner M, Hemmick TK, Hester T, Heuser JM, He X, Hiejima H, Hill JC, Hobbs R, Hohlmann M, Holmes M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Hur MG, Ichihara T, Imai K, Inaba M, Inoue Y, Isenhower D, Isenhower L, Ishihara M, Isobe T, Issah M, Isupov A, Jacak BV, Jia J, Jin J, Jinnouchi O, Johnson BM, Joo KS, Jouan D, Kajihara F, Kametani S, Kamihara N, Kamin J, Kaneta M, Kang JH, Kanou H, Kawagishi T, Kawall D, Kazantsev AV, Kelly S, Khanzadeev A, Kikuchi J, Kim DH, Kim DJ, Kim E, Kim YS, Kinney E, Kiss A, Kistenev E, Kiyomichi A, Klay J, Klein-Boesing C, Kochenda L, Kochetkov V, Komkov B, Konno M, Kotchetkov D, Kozlov A, Král A, Kravitz A, Kroon PJ, Kubart J, Kunde GJ, Kurihara N, Kurita K, Kweon MJ, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Lebedev A, Le Bornec Y, Leckey S, Lee DM, Lee MK, Lee T, Leitch MJ, Leite MAL, Lenzi B, Lim H, Liska T, Litvinenko A, Liu MX, Li X, Li XH, Love B, Lynch D, Maguire CF, Makdisi YI, Malakhov A, Malik MD, Manko VI, Mao Y, Masek L, Masui H, Matathias F, McCain MC, McCumber M, McGaughey PL, Miake Y, Mikes P, Miki K, Miller TE, Milov A, Mioduszewski S, Mishra GC, Mishra M, Mitchell JT, Mitrovski M, Morreale A, Morrison DP, Moss JM, Moukhanova TV, Mukhopadhyay D, Murata J, Nagamiya S, Nagata Y, Nagle JL, Naglis M, Nakagawa I, Nakamiya Y, Nakamura T, Nakano K, Newby J, Nguyen M, Norman BE, Nyanin AS, Nystrand J, O'Brien E, Oda SX, Ogilvie CA, Ohnishi H, Ojha ID, Okada H, Okada K, Oka M, Omiwade OO, Oskarsson A, Otterlund I, Ouchida M, Ozawa K, Pak R, Pal D, Palounek APT, Pantuev V, Papavassiliou V, Park J, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Pinkenburg C, Pisani RP, Purschke ML, Purwar AK, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Rembeczki S, Reuter M, Reygers K, Riabov V, Riabov Y, Roche G, Romana A, Rosati M, Rosendahl SSE, Rosnet P, Rukoyatkin P, Rykov VL, Ryu SS, Sahlmueller B, Saito N, Sakaguchi T, Sakai S, Sakata H, Samsonov V, Sato HD, Sato S, Sawada S, Seele J, Seidl R, Semenov V, Seto R, Sharma D, Shea TK, Shein I, Shevel A, Shibata TA, Shigaki K, Shimomura M, Shohjoh T, Shoji K, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh CP, Singh V, Skutnik S, Slunecka M, Smith WC, Soldatov A, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Staley F, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Suire C, Sullivan JP, Sziklai J, Tabaru T, Takagi S, Takagui EM, Taketani A, Tanaka KH, Tanaka Y, Tanida K, Tannenbaum MJ, Taranenko A, Tarján P, Thomas TL, Togawa M, Toia A, Tojo J, Tomásek L, Torii H, Towell RS, Tram VN, Tserruya I, Tsuchimoto Y, Tuli SK, Tydesjö H, Tyurin N, Vale C, Valle H, van Hecke HW, Velkovska J, Vertesi R, Vinogradov AA, Virius M, Vrba V, Vznuzdaev E, Wagner M, Walker D, Wang XR, Watanabe Y, Wessels J, White SN, Willis N, Winter D, Woody CL, Wysocki M, Xie W, Yamaguchi Y, Yanovich A, Yasin Z, Ying J, Yokkaichi S, Young GR, Younus I, Yushmanov IE, Zajc WA, Zaudtke O, Zhang C, Zhou S, Zimányi J, Zolin L. J/psi production versus centrality, transverse momentum, and rapidity in Au+Au collisions at square root sNN=200 GeV. PHYSICAL REVIEW LETTERS 2007; 98:232301. [PMID: 17677901 DOI: 10.1103/physrevlett.98.232301] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/12/2006] [Indexed: 05/16/2023]
Abstract
The PHENIX experiment at the BNL Relativistic Heavy Ion Collider (RHIC) has measured J/psi production for rapidities -2.2<y<2.2 in Au+Au collisions at square root sNN=200 GeV. The J/psi invariant yield and nuclear modification factor RAA as a function of centrality, transverse momentum, and rapidity are reported. A suppression of J/psi relative to binary collision scaling of proton-proton reaction yields is observed. Models which describe the lower energy J/psi data at the CERN Super Proton Synchrotron invoking only J/psi destruction based on the local medium density predict a significantly larger suppression at RHIC and more suppression at midrapidity than at forward rapidity. Both trends are contradicted by our data.
Collapse
|
118
|
Oka M, Kamo T, Sasaki E, Kaji H, Nishizawa H, Imanishi Y, Nishigori C. A case of phosphaturic mesenchymal tumour (mixed connective tissue variant) that developed in the subcutaneous tissue of a patient with oncogenic osteomalacia and produced fibroblast growth factor 23. Br J Dermatol 2007; 157:198-200. [PMID: 17489977 DOI: 10.1111/j.1365-2133.2007.07940.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
119
|
Berman JD, Oka M, Aikawa M. Fine Structural Alterations inTrypanosoma rhodesienseGrown In Vitro, Treated with WR 1635771. ACTA ACUST UNITED AC 2007; 31:184-6. [PMID: 6547485 DOI: 10.1111/j.1550-7408.1984.tb04315.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Fine-structural alterations in Trypanosoma rhodesiense trypomastigotes exposed to WR 163577, a prophylactic agent against animal African trypanosomiasis, were determined from cells grown in vitro. Exposure of trypomastigotes to a low concentration of drug resulted only in condensation of kinetoplast DNA fibrils. Exposure to higher drug concentrations caused clumping of nuclear chromatin and of cytoplasmic contents. Although alteration of kinetoplast DNA is the first detectable drug-induced change, the function of the kinetoplast in mammalian forms of African trypanosomes is unclear, and the secondary changes in the nucleus and cytoplasm may constitute the functionally significant alterations caused by WR 163577.
Collapse
|
120
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Al-Jamel A, Aoki K, Aphecetche L, Armendariz R, Aronson SH, Asai J, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Baksay G, Baksay L, Baldisseri A, Barish KN, Barnes PD, Bassalleck B, Bathe S, Batsouli S, Baublis V, Bauer F, Bazilevsky A, Belikov S, Bennett R, Berdnikov Y, Bickley AA, Bjorndal MT, Boissevain JG, Borel H, Boyle K, Brooks ML, Brown DS, Bucher D, Buesching H, Bumazhnov V, Bunce G, Burward-Hoy JM, Butsyk S, Campbell S, Chai JS, Chang BS, Charvet JL, Chernichenko S, Chiba J, Chi CY, Chiu M, Choi IJ, Chujo T, Chung P, Churyn A, Cianciolo V, Cleven CR, Cobigo Y, Cole BA, Comets MP, Constantin P, Csanád M, Csörgo T, Dahms T, Das K, David G, Deaton MB, Dehmelt K, Delagrange H, Denisov A, d'Enterria D, Deshpande A, Desmond EJ, Dietzsch O, Dion A, Donadelli M, Drachenberg JL, Drapier O, Drees A, Dubey AK, Durum A, Dzhordzhadze V, Efremenko YV, Egdemir J, Ellinghaus F, Emam WS, Enokizono A, En'yo H, Espagnon B, Esumi S, Eyser KO, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Forestier B, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fung SY, Fusayasu T, Gadrat S, Garishvili I, Gastineau F, Germain M, Glenn A, Gong H, Gonin M, Gosset J, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Gustafsson HA, Hachiya T, Hadj Henni A, Haegemann C, Haggerty JS, Hagiwara MN, Hamagaki H, Han R, Harada H, Hartouni EP, Haruna K, Harvey M, Haslum E, Hasuko K, Hayano R, Heffner M, Hemmick TK, Hester T, Heuser JM, He X, Hiejima H, Hill JC, Hobbs R, Hohlmann M, Holmes M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Hur MG, Ichihara T, Imai K, Inaba M, Inoue Y, Isenhower D, Isenhower L, Ishihara M, Isobe T, Issah M, Isupov A, Jacak BV, Jia J, Jin J, Jinnouchi O, Johnson BM, Joo KS, Jouan D, Kajihara F, Kametani S, Kamihara N, Kamin J, Kaneta M, Kang JH, Kano H, Kanou H, Kawagishi T, Kawall D, Kazantsev AV, Kelly S, Khanzadeev A, Kikuchi J, Kim DH, Kim DJ, Kim E, Kim YS, Kinney E, Kiss A, Kistenev E, Kiyomichi A, Klay J, Klein-Boesing C, Kochenda L, Kochetkov V, Komkov B, Konno M, Kotchetkov D, Kozlov A, Král A, Kravitz A, Kroon PJ, Kubart J, Kunde GJ, Kurihara N, Kurita K, Kweon MJ, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Lebedev A, Le Bornec Y, Leckey S, Lee DM, Lee MK, Lee T, Leitch MJ, Leite MAL, Lenzi B, Lim H, Liska T, Litvinenko A, Liu MX, Li X, Li XH, Love B, Lynch D, Maguire CF, Makdisi YI, Malakhov A, Malik MD, Manko VI, Mao Y, Masek L, Masui H, Matathias F, McCain MC, McCumber M, McGaughey PL, Miake Y, Mikes P, Miki K, Miller TE, Milov A, Mioduszewski S, Mishra GC, Mishra M, Mitchell JT, Mitrovski M, Morreale A, Morrison DP, Moss JM, Moukhanova TV, Mukhopadhyay D, Murata J, Nagamiya S, Nagata Y, Nagle JL, Naglis M, Nakagawa I, Nakamiya Y, Nakamura T, Nakano K, Newby J, Nguyen M, Norman BE, Nyanin AS, Nystrand J, O'Brien E, Oda SX, Ogilvie CA, Ohnishi H, Ojha ID, Okada H, Okada K, Oka M, Omiwade OO, Oskarsson A, Otterlund I, Ouchida M, Ozawa K, Pak R, Pal D, Palounek APT, Pantuev V, Papavassiliou V, Park J, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Pinkenburg C, Pisani RP, Purschke ML, Purwar AK, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Rembeczki S, Reuter M, Reygers K, Riabov V, Riabov Y, Roche G, Romana A, Rosati M, Rosendahl SSE, Rosnet P, Rukoyatkin P, Rykov VL, Ryu SS, Sahlmueller B, Saito N, Sakaguchi T, Sakai S, Sakata H, Samsonov V, Sato HD, Sato S, Sawada S, Seele J, Seidl R, Semenov V, Seto R, Sharma D, Shea TK, Shein I, Shevel A, Shibata TA, Shigaki K, Shimomura M, Shohjoh T, Shoji K, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh CP, Singh V, Skutnik S, Slunecka M, Smith WC, Soldatov A, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Staley F, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Suire C, Sullivan JP, Sziklai J, Tabaru T, Takagi S, Takagui EM, Taketani A, Tanaka KH, Tanaka Y, Tanida K, Tannenbaum MJ, Taranenko A, Tarján P, Thomas TL, Togawa M, Toia A, Tojo J, Tomásek L, Torii H, Towell RS, Tram VN, Tserruya I, Tsuchimoto Y, Tuli SK, Tydesjö H, Tyurin N, Vale C, Valle H, van Hecke HW, Velkovska J, Vertesi R, Vinogradov AA, Virius M, Vrba V, Vznuzdaev E, Wagner M, Walker D, Wang XR, Watanabe Y, Wessels J, White SN, Willis N, Winter D, Woody CL, Wysocki M, Xie W, Yamaguchi YL, Yanovich A, Yasin Z, Ying J, Yokkaichi S, Young GR, Younus I, Yushmanov IE, Zajc WA, Zaudtke O, Zhang C, Zhou S, Zimányi J, Zolin L. Scaling properties of azimuthal anisotropy in Au+Au and Cu+Cu Collisions at sqrt[s NN]=200 GeV. PHYSICAL REVIEW LETTERS 2007; 98:162301. [PMID: 17501413 DOI: 10.1103/physrevlett.98.162301] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/16/2006] [Indexed: 05/15/2023]
Abstract
Differential measurements of elliptic flow (v2) for Au+Au and Cu+Cu collisions at sqrt[sNN]=200 GeV are used to test and validate predictions from perfect fluid hydrodynamics for scaling of v2 with eccentricity, system size, and transverse kinetic energy (KE T). For KE T identical with mT-m up to approximately 1 GeV the scaling is compatible with hydrodynamic expansion of a thermalized fluid. For large values of KE T mesons and baryons scale separately. Quark number scaling reveals a universal scaling of v2 for both mesons and baryons over the full KE T range for Au+Au. For Au+Au and Cu+Cu the scaling is more pronounced in terms of KE T, rather than transverse momentum.
Collapse
|
121
|
Enomoto S, Yahagi N, Fujishiro M, Oka M, Kakushima N, Iguchi M, Yanaoka K, Arii K, Tamai H, Shimizu Y, Omata M, Ichinose M. Novel endoscopic hemostasis technique for use during endoscopic submucosal dissection. Endoscopy 2007; 39 Suppl 1:E156. [PMID: 16775794 DOI: 10.1055/s-2006-925254] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
|
122
|
Shibahara Y, Oka M, Tominaga K, Ii T, Umeda M, Uneo N, Abe A, Ohashi E, Ushio H, Shiomi K. Determination of Crustacean Allergen in Food Products by Sandwich ELISA. J JPN SOC FOOD SCI 2007. [DOI: 10.3136/nskkk.54.280] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
123
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Aoki K, Aphecetche L, Armendariz R, Aronson SH, Asai J, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Baksay G, Baksay L, Baldisseri A, Barish KN, Barnes PD, Bassalleck B, Bathe S, Batsouli S, Baublis V, Bazilevsky A, Belikov S, Bennett R, Berdnikov Y, Bickley AA, Boissevain JG, Borel H, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Campbell S, Chang BS, Charvet JL, Chernichenko S, Chiba J, Chi CY, Chiu M, Choi IJ, Chujo T, Chung P, Churyn A, Cianciolo V, Cleven CR, Cole BA, Comets MP, Constantin P, Csanád M, Csörgo T, Dahms T, Das K, David G, Deaton MB, Dehmelt K, Delagrange H, Denisov A, d'Enterria D, Deshpande A, Desmond EJ, Dietzsch O, Dion A, Donadelli M, Drapier O, Drees A, Dubey AK, Durum A, Dzhordzhadze V, Efremenko YV, Egdemir J, Ellinghaus F, Emam WS, Enokizono A, En'yo H, Esumi S, Eyser KO, Fields DE, Finger M, Fleuret F, Fokin SL, Fraenkel Z, Franz A, Frantz J, Frawley AD, Fujiwara K, Fukao Y, Fusayasu T, Gadrat S, Garishvili I, Glenn A, Gong H, Gonin M, Gosset J, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Gustafsson HA, Hachiya T, Henni AH, Haegemann C, Haggerty JS, Hamagaki H, Han R, Harada H, Hartouni EP, Haruna K, Haslum E, Hayano R, Heffner M, Hemmick TK, Hester T, He X, Hiejima H, Hill JC, Hobbs R, Hohlmann M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Ichihara T, Imai K, Inaba M, Inoue Y, Isenhower D, Isenhower L, Ishihara M, Isobe T, Issah M, Isupov A, Jacak BV, Jia J, Jin J, Jinnouchi O, Johnson BM, Joo KS, Jouan D, Kajihara F, Kametani S, Kamihara N, Kamin J, Kaneta M, Kang JH, Kanou H, Kano H, Kawall D, Kazantsev AV, Khanzadeev A, Kikuchi J, Kim DH, Kim DJ, Kim E, Kinney E, Kiss A, Kistenev E, Kiyomichi A, Klay J, Klein-Boesing C, Kochenda L, Kochetkov V, Komkov B, Konno M, Kotchetkov D, Kozlov A, Král A, Kravitz A, Kubart J, Kunde GJ, Kurihara N, Kurita K, Kweon MJ, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Lebedev A, Lee DM, Lee MK, Lee T, Leitch MJ, Leite MAL, Lenzi B, Liska T, Litvinenko A, Liu MX, Li X, Love B, Lynch D, Maguire CF, Makdisi YI, Malakhov A, Malik MD, Manko VI, Mao Y, Masek L, Masui H, Matathias F, McCumber M, McGaughey PL, Miake Y, Mikes P, Miki K, Miller TE, Milov A, Mioduszewski S, Mishra M, Mitchell JT, Mitrovski M, Morreale A, Morrison DP, Moukhanova TV, Mukhopadhyay D, Murata J, Nagamiya S, Nagata Y, Nagle JL, Naglis M, Nakagawa I, Nakamiya Y, Nakamura T, Nakano K, Newby J, Nguyen M, Norman BE, Nyanin AS, O'Brien E, Oda SX, Ogilvie CA, Ohnishi H, Okada H, Okada K, Oka M, Omiwade OO, Oskarsson A, Ouchida M, Ozawa K, Pak R, Pal D, Palounek APT, Pantuev V, Papavassiliou V, Park J, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Pinkenburg C, Purschke ML, Purwar AK, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Rembeczki S, Reuter M, Reygers K, Riabov V, Riabov Y, Roche G, Romana A, Rosati M, Rosendahl SSE, Rosnet P, Rukoyatkin P, Rykov VL, Sahlmueller B, Saito N, Sakaguchi T, Sakai S, Sakata H, Samsonov V, Sato S, Sawada S, Seele J, Seidl R, Semenov V, Seto R, Sharma D, Shein I, Shevel A, Shibata TA, Shigaki K, Shimomura M, Shoji K, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh CP, Singh V, Skutnik S, Slunecka M, Soldatov A, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Staley F, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Suire C, Sziklai J, Tabaru T, Takagi S, Takagui EM, Taketani A, Tanaka Y, Tanida K, Tannenbaum MJ, Taranenko A, Tarján P, Thomas TL, Togawa M, Toia A, Tojo J, Tomásek L, Torii H, Towell RS, Tram VN, Tserruya I, Tsuchimoto Y, Vale C, Valle H, van Hecke HW, Velkovska J, Vertesi R, Vinogradov AA, Virius M, Vrba V, Vznuzdaev E, Wagner M, Walker D, Wang XR, Watanabe Y, Wessels J, White SN, Winter D, Woody CL, Wysocki M, Xie W, Yamaguchi Y, Yanovich A, Yasin Z, Ying J, Yokkaichi S, Young GR, Younus I, Yushmanov IE, Zajc WA, Zaudtke O, Zhang C, Zhou S, Zimányi J, Zolin L. Measurement of high-pT single electrons from heavy-flavor decays in p + p collisions at square root of s = 200 GeV. PHYSICAL REVIEW LETTERS 2006; 97:252002. [PMID: 17280343 DOI: 10.1103/physrevlett.97.252002] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/06/2006] [Indexed: 05/13/2023]
Abstract
The momentum distribution of electrons from decays of heavy flavor (charm and bottom) for midrapidity absolute value of y < 0.35 in p + p collisions at square root of s = 200 GeV has been measured by the PHENIX experiment at the BNL Relativistic Heavy Ion Collider over the transverse momentum range 0.3 < pT < 9 GeV/c. Two independent methods have been used to determine the heavy-flavor yields, and the results are in good agreement with each other. A fixed-order-plus-next-to-leading-log perturbative QCD calculation agrees with the data within the theoretical and experimental uncertainties, with the data/theory ratio of 1.71+/-0.02stat+/-0.18sys for 0.3 < pT < 9 GeV/c. The total charm production cross section at this energy has also been deduced to be sigma cc = 567+/-57stat+/-193sys microb.
Collapse
|
124
|
Fujishiro M, Yahagi N, Kakushima N, Kodashima S, Muraki Y, Ono S, Kobayashi K, Hashimoto T, Yamamichi N, Tateishi A, Shimizu Y, Oka M, Ogura K, Kawabe T, Ichinose M, Omata M. Successful nonsurgical management of perforation complicating endoscopic submucosal dissection of gastrointestinal epithelial neoplasms. Endoscopy 2006; 38:1001-6. [PMID: 17058165 DOI: 10.1055/s-2006-944775] [Citation(s) in RCA: 123] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND AND STUDY AIMS Endoscopic submucosal dissection (ESD) is a novel technique used for the treatment of gastrointestinal neoplasia. One of its major limitations, however, is the complication of perforation. PATIENTS AND METHODS We included in our study all the cases of perforation that occurred during ESD procedures for gastrointestinal epithelial neoplasia between February 2000 and February 2005. Clinical outcomes after perforation were investigated. RESULTS Perforation was experienced at 27 lesions in 27 patients (four in the esophagus, fourteen in the stomach, seven in the colon, and two in the rectum). Fibrosis under the lesions was confirmed histologically in seven patients (26 %). Immediate closure using endoclips was performed in all patients except for three asymptomatic patients in whom a stomach perforation was first noticed when free air was noticed on a radiograph the morning after the ESD procedure. Air accumulation was detected radiographically in 21 patients (78 %). The mean duration of antibiotic treatment was 6.7 days and the patients were fasted for a mean period of 5.3 days. The mean maximum body temperature was 37.3 degrees C, the mean white blood cell count was 9733/mm3, and the mean C-reactive protein level was 5.0 mg/dl. All the patients were discharged well from the ward after a mean time of 12.1 days after ESD, and no recurrence caused by tumor spread from the perforation occurred in any patient after a median follow-up period of 36 months (range 9 - 52 months). CONCLUSION Successful nonsurgical management after ESD complicated by perforation is a highly feasible option if intensive conservative treatments are used following immediate endoscopic closure of the perforation.
Collapse
|
125
|
Akiba S, Mukaida Y, Hane K, Oka M, Uozumi N, Shimizu T, Sato T. Group IVA phospholipase A2-mediated production of fibronectin by oxidized LDL in mesangial cells. Kidney Int 2006; 70:1013-8. [PMID: 16837927 DOI: 10.1038/sj.ki.5001631] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The deposition of atherogenic lipoproteins such as oxidized low-density lipoprotein (oxLDL) within the mesangium is involved in the overproduction of extracellular matrix proteins, a key event in the progression of glomerular diseases including glomerulosclerosis. To clarify the mechanisms underlying the oxLDL-induced production of extracellular matrix proteins, we examined the possible involvement of group IVA phospholipase A(2) (PLA(2)) using human mesangial cells and group IVA PLA(2)-deficient mouse mesangial cells. oxLDL accelerated the production of fibronectin and collagen (type IV), components of extracellular matrix proteins, with the preceding release of arachidonic acid. Methyl arachidonyl fluorophosphonate (MAFP), known as an inhibitor of group IVA PLA(2), markedly suppressed the oxLDL-induced production of fibronectin as well as the release of arachidonic acid, whereas it did not inhibit the production of collagen. The inhibitory effect of MAFP on the production of fibronectin was reversed by adding arachidonic acid and 12-hydroxyeicosatetraenoic acid. Furthermore, we found that in group IVA PLA(2)-deficient mouse mesangial cells, the production of fibronectin in response to oxLDL was weak as compared with that in wild-type cells. However, the production by oxLDL of collagen was not suppressed in the group IVA PLA(2)-deficient cells. These findings suggest that group IVA PLA(2) is involved in the production of fibronectin in oxLDL-stimulated mesangial cells.
Collapse
|